183 related articles for article (PubMed ID: 35135832)
1. Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis.
Medeiros-Ribeiro AC; Bonfiglioli KR; Domiciano DS; Shimabuco AY; da Silva HC; Saad CGS; Yuki EFN; Pasoto SG; Araujo CSR; Nakai TL; Silva CA; Pedrosa T; Kupa LVK; Silva MSR; Balbi GGM; Kallas EG; Aikawa NE; Bonfa E
Ann Rheum Dis; 2022 May; 81(5):710-719. PubMed ID: 35135832
[TBL] [Abstract][Full Text] [Related]
2. Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis.
G S Saad C; S R Silva M; Sampaio-Barros PD; C B Moraes J; G Schainberg C; Gonçalves CR; Shimabuco AY; Aikawa NE; F N Yuki E; G Pasoto S; V K Kupa L; K Aoyama R; S R Araujo C; Silva CA; Medeiros-Ribeiro AC; Bonfa E
Joint Bone Spine; 2023 Jan; 90(1):105464. PubMed ID: 36150668
[TBL] [Abstract][Full Text] [Related]
3. Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial.
Araujo CSR; Medeiros-Ribeiro AC; Saad CGS; Bonfiglioli KR; Domiciano DS; Shimabuco AY; Silva MSR; Yuki EFN; Pasoto SG; Pedrosa T; Kupa LVK; Zou G; Pereira RMR; Silva CA; Aikawa NE; Bonfa E
Ann Rheum Dis; 2022 Jun; 81(6):889-897. PubMed ID: 35193873
[TBL] [Abstract][Full Text] [Related]
4. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2.
Shinjo SK; de Souza FHC; Borges IBP; Dos Santos AM; Miossi R; Misse RG; Medeiros-Ribeiro AC; Saad CGS; Yuki EFN; Pasoto SG; Kupa LVK; Ceneviva C; Seraphim JC; Pedrosa TN; Vendramini MBG; Silva CA; Aikawa NE; Bonfá E
Rheumatology (Oxford); 2022 Aug; 61(8):3351-3361. PubMed ID: 34664616
[TBL] [Abstract][Full Text] [Related]
5. Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases.
Aikawa NE; Kupa LVK; Medeiros-Ribeiro AC; Saad CGS; Yuki EFN; Pasoto SG; Rojo PT; Pereira RMR; Shinjo SK; Sampaio-Barros PD; Andrade DCO; Halpern ASR; Fuller R; Souza FHC; Guedes LKN; Assad APL; Moraes JCB; Lopes MRU; Martins VAO; Betancourt L; Ribeiro CT; Sales LP; Bertoglio IM; Bonoldi VLN; Mello RLP; Balbi GGM; Sartori AMC; Antonangelo L; Silva CA; Bonfa E
Ann Rheum Dis; 2022 Jul; 81(7):1036-1043. PubMed ID: 35277389
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis.
Farroni C; Picchianti-Diamanti A; Aiello A; Nicastri E; Laganà B; Agrati C; Castilletti C; Meschi S; Colavita F; Cuzzi G; Casetti R; Grassi G; Petrone L; Vanini V; Salmi A; Repele F; Altera AMG; Maffongelli G; Corpolongo A; Salemi S; Di Rosa R; Nalli G; Sesti G; Vaia F; Puro V; Goletti D
Front Immunol; 2022; 13():846753. PubMed ID: 35309297
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy.
Sampaio-Barros PD; Medeiros-Ribeiro AC; Luppino-Assad AP; Miossi R; da Silva HC; Yuki EFVN; Pasoto SG; Saad CGS; Silva CA; Kupa LVK; Deveza GBH; Pedrosa TN; Aikawa NE; Bonfá E
Rheumatology (Oxford); 2022 Jun; 61(SI2):SI169-SI174. PubMed ID: 34894235
[TBL] [Abstract][Full Text] [Related]
8. Impact of Distinct Therapies on Antibody Response to SARS-CoV-2 Vaccine in Systemic Lupus Erythematosus.
Yuki EFN; Borba EF; Pasoto SG; Seguro LP; Lopes M; Saad CGS; Medeiros-Ribeiro AC; Silva CA; de Andrade DCO; Kupa LVK; Betancourt L; Bertoglio I; Valim J; Hoff C; Formiga FFC; Pedrosa T; Kallas EG; Aikawa NE; Bonfa E
Arthritis Care Res (Hoboken); 2022 Apr; 74(4):562-571. PubMed ID: 34806342
[TBL] [Abstract][Full Text] [Related]
9. Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination.
Andreica I; Blazquez-Navarro A; Sokolar J; Anft M; Kiltz U; Pfaender S; Vidal Blanco E; Westhoff T; Babel N; Stervbo U; Baraliakos X
RMD Open; 2022 Sep; 8(2):. PubMed ID: 36104115
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis.
Jansen JP; Buckley F; Dejonckheere F; Ogale S
Health Qual Life Outcomes; 2014 Jul; 12():102. PubMed ID: 24988902
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of Inactivated SARS-CoV-2 Vaccines in Patients With Rheumatoid Arthritis: A Case Series.
Zhao T; Shen J; Zhu Y; Tian X; Wen G; Wei Y; Xu B; Fu C; Xie Z; Xi Y; Li Z; Peng J; Wu Y; Tang X; Wan C; Pan L; Li Z; Qin D
Front Public Health; 2022; 10():875558. PubMed ID: 35548080
[TBL] [Abstract][Full Text] [Related]
12. Janus kinase (JAK) inhibitors significantly reduce the humoral vaccination response against SARS-CoV-2 in patients with rheumatoid arthritis.
Schäfer A; Kovacs MS; Eder A; Nigg A; Feuchtenberger M
Clin Rheumatol; 2022 Dec; 41(12):3707-3714. PubMed ID: 35965290
[TBL] [Abstract][Full Text] [Related]
13. Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose.
Pereira RMR; Dagostin MA; Caparbo VF; Sales LP; Pasoto SG; Silva CA; Yuki EFN; Saad CGS; Medeiros-Ribeiro AC; Kupa LVK; Fusco SRG; Martins VAO; Martins CCMF; Barbas CV; Shinjo SK; Aikawa NE; Bonfa E
Clinics (Sao Paulo); 2023; 78():100150. PubMed ID: 36529052
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study.
Netto LC; Ibrahim KY; Picone CM; Alves APPS; Aniceto EV; Santiago MR; Parmejani PSS; Aikawa NE; Medeiros-Ribeiro AC; Pasoto SG; Yuki EFN; Saad CGS; Pedrosa T; Lara AN; Ceneviva C; Bonfa E; Kallas EG; Avelino-Silva VI
Lancet HIV; 2022 May; 9(5):e323-e331. PubMed ID: 35338835
[TBL] [Abstract][Full Text] [Related]
15. Immune Response to SARS-CoV-2 Third Vaccine in Patients With Rheumatoid Arthritis Who Had No Seroconversion After Primary 2-Dose Regimen With Inactivated or Vector-Based Vaccines.
Isnardi CA; Cerda OL; Landi M; Cruces L; Schneeberger EE; Montoro CC; Alfaro MA; Roldán BM; Gómez Vara AB; Giorgis P; Ezquer RA; Crespo Rocha MG; Reyes Gómez CR; de Los Ángeles Correa M; Rosemffet MG; Abarza VC; Pellet SC; Perandones M; Reimundes C; Longueira Y; Turk G; Quiroga MF; Laufer N; Quintana R; de la Vega MC; Kreplak N; Pifano M; Maid P; Pons-Estel GJ; Citera G
J Rheumatol; 2022 Dec; 49(12):1385-1389. PubMed ID: 36182107
[TBL] [Abstract][Full Text] [Related]
16. Inactivated SARS-CoV-2 vaccine in primary Sjögren's syndrome: humoral response, safety, and effects on disease activity.
Pasoto SG; Halpern ASR; Guedes LKN; Ribeiro ACM; Yuki ENF; Saad CGS; da Silva CAA; de Vinci Kanda Kupa L; Villamarín LEB; de Oliveira Martins VA; Martins CCMF; Deveza GBH; Leon EP; Bueno C; Pedrosa TN; Santos REB; Soares R; Aikawa NE; Bonfa E
Clin Rheumatol; 2022 Jul; 41(7):2079-2089. PubMed ID: 35306594
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses.
Saleem B; Ross RL; Bissell LA; Aslam A; Mankia K; Duquenne L; Corsadden D; Carter C; Hughes P; Nadat FA; Mulipa P; Lobb M; Clarke B; Mbara K; Morton R; Dibb S; Chowdhury R; Newton D; Pike A; Kakkar V; Savic S; DelGaldo F; Emery P
RMD Open; 2022 Mar; 8(1):. PubMed ID: 35365569
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome.
Signorelli F; Balbi GGM; Aikawa NE; Silva CA; Kupa LVK; Medeiros-Ribeiro AC; Yuki EF; Pasoto SG; Saad CG; Borba EF; Seguro LPC; Pedrosa T; Oliveira VAA; Costa ALCS; Ribeiro CT; Santos REB; Andrade DCO; Bonfá E
Lupus; 2022 Jul; 31(8):974-984. PubMed ID: 35593174
[TBL] [Abstract][Full Text] [Related]
19. Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine.
Aikawa NE; Kupa LVK; Silva CA; Saad CGS; Pasoto SG; Yuki EFN; Fusco SRG; Shinjo SK; Andrade DCO; Sampaio-Barros PD; Pereira RMR; Chasin ACS; Shimabuco AY; Luppino-Assad AP; Leon EP; Lopes MH; Antonangelo L; Medeiros-Ribeiro AC; Bonfa E
Rheumatology (Oxford); 2022 Dec; 62(1):480-485. PubMed ID: 35639644
[TBL] [Abstract][Full Text] [Related]
20. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine.
Kapetanovic MC; Nagel J; Nordström I; Saxne T; Geborek P; Rudin A
Vaccine; 2017 Feb; 35(6):903-908. PubMed ID: 28081972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
